Skip to main content

Gabriel Ig Camiña Rodríguez

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Gabriel Ig Camiña Rodríguez

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, SGR-Cat 2021: Neuroimmunologia Clínica, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, SGR-Cat 2021: Neuroimmunologia Clínica, M Jesus Arevalo Navines, SGR-Cat 2021: Neuroimmunologia Clínica, Augusto Cesar Sao Aviles, SGR-Cat 2021: Neuroimmunologia Clínica, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, SGR-Cat 2021: Neuroimmunologia Clínica, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

IP: -
Collaborators: Carlos Nos Llopis, Gabriel Ig Camiña Rodríguez, Ana Zabalza de Torres, Luciana Midaglia Fernandez
Funding agency: The Innovative Medicines Initiative
Funding: 552235
Reference: RADAR_X.MONTALBAN_IMI2_2015
Duration: 01/04/2016 - 31/03/2022

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Ana Martinez Alcazar

Ana Martinez Alcazar

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Ana Maria Herraiz Diaz

Ana Maria Herraiz Diaz

Research assistant
Multidisciplinary Nursing Research Group
Read more
Pol Miguel Puigbarraca

Pol Miguel Puigbarraca

Predoctoral researcher
Multidisciplinary Nursing Research Group
Read more
Marta Altayo Carulla

Marta Altayo Carulla

Research assistant
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.